Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open firm
Thu, 25 Oct 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in China (down 0.2%) and South Korea (down 0.1%) leading the losses in the region. However, markets in Japan (up 0.4%) and Singapore (up 0.3%) are trading firm. The Indian share market indices have opened the day with marginal gains. Stocks in the oil & gas and metal space are leading the gains. However, IT andFMCG stocks are trading weak.

The Sensex today is up by around 16 points (0.1%), while the NSE-Nifty is up by around 3 points (0.1%). Mid and small cap stocks are trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.2% and 0.4% respectively. The rupee is trading at Rs 53.72 to the US dollar.

Auto stocks have opened the day on a firm note with Bajaj Auto, Mahindra & Mahindra (M&M) and Hero MotoCorp leading the gains. As per a leading financial daily, India's second largest two-wheeler maker Bajaj Auto is set to launch its most expensive bike in the 100 cc segment in January 2013. According to the company's President (Motorcycle Business) K Srinivas, it will also be the most technologically advanced bike. However, the company has not revealed the price range of the bike. It must be noted that Bajaj Auto presently sells 100cc bikes under the Platina and Discover range. These bikes are priced between Rs 38,990 and 44,497. During the July-September quarter of the financial year 2012-13, the company's market share stood at 27%.

Indian pharma stocks have opened the day on a mixed note with Indoco Remedies, Glenmark Pharma and IPCA Labs leading the gains. However, Sun Pharma and Cipla are facing selling pressure. In a bid to boost sales in the US which is the world's biggest drug market, Indian drugmaker Lupin is planning to launch at least 15 new generic products in the country in the current financial year ending March 2013. As per Vinita Gupta, chief executive of Lupin's US unit, about 8 to 10 of the 15 new products are likely to be oral contraceptives. It must be noted that the company has launched 5 products in the US in the current fiscal year so far. During the second quarter of the financial year 2012-13 (2QFY13), while the company's net sales increased by 29% year-on-year to Rs 22.39 bn, the net profits rose by 9% YoY to Rs 2.9 bn.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.